Kyverna Secures ElevateBio for Miv-cel Commercial Manufacturing Ahead of Potential FDA Nod
Event summary
- Kyverna Therapeutics has signed a commercial manufacturing and supply agreement with ElevateBio for its lead CAR T-cell therapy, miv-cel.
- The deal covers U.S. commercial and global clinical supply of miv-cel, supporting potential launches in stiff person syndrome (SPS) and generalized myasthenia gravis (gMG).
- Kyverna aims to complete its rolling BLA submission for miv-cel in SPS by Q4 2026.
- ElevateBio claims a >98% clinical manufacturing success rate for miv-cel, with the partnership spanning three years of process development and optimization.
The big picture
This agreement underscores the growing collaboration between biopharmaceutical companies and specialized CDMOs like ElevateBio to ensure reliable supply chains for complex cell therapies. Kyverna’s strategic move comes as CAR T-cell therapies expand beyond oncology into autoimmune diseases, a market with significant unmet needs but higher manufacturing challenges due to patient-specific customization.
What we're watching
- Regulatory Timeline
- Whether Kyverna can secure FDA approval for miv-cel in SPS by late 2026, positioning it as the first CAR T-cell therapy for an autoimmune disease.
- Manufacturing Scale
- The pace at which ElevateBio can scale production to meet potential demand across multiple indications.
- Pipeline Expansion
- How Kyverna leverages this manufacturing deal to accelerate development in other autoimmune diseases, including gMG and neuroimmunology.